Beat Childhood Cancer offers phase I and phase II clinical trials to children battling childhood cancer. Our focus is on using precision medicine in patients at diagnosis as well as in difficult to treat relapsed and refractory cancers. Our goal is to increase survival and decrease toxicity while targeting the unique factors driving each child’s tumor.
NMTRC006B – An Intermediate Expanded Use Trial of DFMO – Study Record | ClinicalTrials.gov
NMTRC012 – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN) – Study Record | ClinicalTrials.gov
NMTRC014 – Neuroblastoma Maintenance Therapy Trial (NMTT) – Study Record | ClinicalTrials.gov
BCC015 – EFlornithine (DFMO) and Etoposide for Relapsed/ Refractory Neuroblastoma – Study Record | ClinicalTrials.gov
BCC016 – DFMO as Maintenance Therapy for Molecular High/ Very High Risk and Relapsed Medulloblastoma – Study Record | ClinicalTrials.gov
BCC017 – PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (PEACH) – Study Record | ClinicalTrials.gov
BCC018 – Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma – Study Record | ClinicalTrials.gov
LCI-BCC-BIO-001 – Beat Childhood Cancer Specimen Banking and Data Registry – Study Record | ClinicalTrials.gov
Coming soon in 2024 – BCC019, BCC020, and BCC021!